Anticancer effects of the HDAC inhibitor, 3β,6β‑dihydroxyurs‑12‑en‑27‑oic acid, in MCF‑7 breast cancer cells via the inhibition of Akt/mTOR pathways

Lim,Jong Seung; Kyung,So Young; Jeon,Yukyoung; Kim,In Su; Kwak,Jong Hwan; Kim,Hyung Sik

doi:10.3892/or.2023.8480

Anticancer effects of the HDAC inhibitor, 3β,6β‑dihydroxyurs‑12‑en‑27‑oic acid, in MCF‑7 breast cancer cells via the inhibition of Akt/mTOR pathways

Authors:
- Jong Seung Lim
- So Young Kyung
- Yukyoung Jeon
- In Su Kim
- Jong Hwan Kwak
- Hyung Sik Kim
View Affiliations

Affiliations: School of Pharmacy, Sungkyunkwan University, Suwon, Gyeonggi-do 16419, Republic of Korea
Published online on: January 12, 2023 https://doi.org/10.3892/or.2023.8480
Article Number: 43
Copyright: © Lim et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Astilbe chinensis (A. chinensis) is a perennial herb that is used to treat chronic bronchitis and pain. The anticancer activity of 3β,6β‑dihydroxyurs‑12‑en‑27‑oic acid (ACT‑3), a major component isolated from A. chinensis, has not yet been investigated in detail. The purpose of the present study was to investigate the histone deacetylase (HDAC) inhibitory and anticancer activities of ACT‑3 compared with suberoylanilide hydroxamic acid (SAHA) in MCF‑7 human breast cancer cells. The purity of ACT‑3 was determined using high‑performance liquid chromatography. In the present study, the effects of ACT‑3 on anticancer effects of MCF‑7 cells were determined by measuring the level of apoptotic cell death and cell cycle regulator using flow cytometry analysis and western blot analysis, respectively. The effects of ACT‑3 on HDAC enzyme activity were measured using assay kits. ACT‑3 and SAHA increased the levels of acetylated histone H3 and reduced the levels of HDAC1 and HDAC3 in MCF‑7 cells. ACT‑3 significantly decreased the cell viability in a concentration‑dependent manner and induced different morphological changes at high concentrations. ACT‑3 and SAHA significantly inhibited the colony formation in MCF‑7 cells. ACT‑3 inhibited total HDAC activity in a dose‑dependent manner. ACT‑3 significantly reduced the expression levels of cyclin D1 and cyclin‑dependent kinase 4, and upregulated the expression levels of p21^WAF1 and p53. A significant increase in the G1 phase cell population was observed in MCF‑7 cells and ACT‑3 induced apoptosis by reducing the ratio of B‑cell lymphoma‑2 (Bcl‑2)/Bcl‑2‑associated X (Bax) and releasing cleaved caspase 9. Additionally, ACT‑3 significantly increased autophagic cell death by inhibiting the serine‑threonine kinase/mammalian target of the rapamycin pathway. Autophagy induction was confirmed via acridine orange staining. ACT‑3 significantly increased the pERK1/2 and p21 in MCF‑7 cells. Thus, the activated ERK pathway played an important role in cell cycle arrest and apoptosis via ERK‑dependent induction of p21 in MCF‑7 cells. These data indicated that ACT‑3 can be used as a promising anticancer agent to overcome the limitations and reduce the side effects of conventional anticancer drugs.

View Figures

View References

1	Pojani E and Barlocco D: Romidepsin (FK228), A histone deacetylase inhibitor and its analogues in cancer chemotherapy. Curr Med Chem. 28:1290–1303. 2021. View Article : Google Scholar : PubMed/NCBI
2	West AC and Johnstone RW: New and emerging HDAC inhibitors for cancer treatment. J Clin Invest. 124:30–39. 2014. View Article : Google Scholar : PubMed/NCBI
3	Bass AKA, El-Zoghbi MS, Nageeb EM, Mohamed MFA, Badr M and Abuo-Rahma GEA: Comprehensive review for anticancer hybridized multitargeting HDAC inhibitors. Eur J Med Chem. 209:1129042021. View Article : Google Scholar : PubMed/NCBI
4	Sanaei M and Kavoosi F: Histone deacetylases and histone deacetylase inhibitors: Molecular mechanisms of action in various cancers. Adv Biomed Res. 8:632019. View Article : Google Scholar : PubMed/NCBI
5	Ediriweera MK, Tennekoon KH and Samarakoon SR: Emerging role of histone deacetylase inhibitors as anti-breast-cancer agents. Drug Discov Today. 24:685–702. 2019. View Article : Google Scholar : PubMed/NCBI
6	Hanikoglu A, Hanikoglu F and Ozben T: Natural product inhibitors of histone deacetylases as new anticancer agents. Curr Protein Pept Sci. 19:333–340. 2018. View Article : Google Scholar : PubMed/NCBI
7	Wawruszak A, Kalafut J, Okon E, Czapinski J, Halasa M, Przybyszewska A, Miziak P, Okla K, Rivero-Muller A and Stepulak A: Histone deacetylase inhibitors and phenotypical transformation of cancer cells. Cancers (Basel). 11:1482019. View Article : Google Scholar : PubMed/NCBI
8	Dawood M, Fleischer E, Klinger A, Bringmann G, Shan L and Efferth T: Inhibition of cell migration and induction of apoptosis by a novel class II histone deacetylase inhibitor, MCC2344. Pharmacol Res. 160:1050762020. View Article : Google Scholar : PubMed/NCBI
9	Suraweera A, O'Byrne KJ and Richard DJ: Combination therapy with histone deacetylase inhibitors (HDACi) for the treatment of cancer: Achieving the full therapeutic potential of HDACi. Front Oncol. 8:922018. View Article : Google Scholar : PubMed/NCBI
10	Mottamal M, Zheng S, Huang TL and Wang G: Histone deacetylase inhibitors in clinical studies as templates for new anticancer agents. Molecules. 20:3898–3941. 2015. View Article : Google Scholar : PubMed/NCBI
11	Chen R, Zhang M, Zhou Y, Guo W, Yi M, Zhang Z, Ding Y and Wang Y: The application of histone deacetylases inhibitors in glioblastoma. J Exp Clin Cancer Res. 39:1382020. View Article : Google Scholar : PubMed/NCBI
12	Momenimovahed Z and Salehiniya H: Epidemiological characteristics of and risk factors for breast cancer in the world. Breast Cancer (Dove Med Press). 11:151–164. 2019.PubMed/NCBI
13	Damaskos C, Garmpis N, Valsami S, Kontos M, Spartalis E, Kalampokas T, Kalampokas E, Athanasiou A, Moris D, Daskalopoulou A, et al: Histone deacetylase inhibitors: An attractive therapeutic strategy against breast cancer. Anticancer Res. 37:35–46. 2017. View Article : Google Scholar : PubMed/NCBI
14	Naimo GD, Gelsomino L, Catalano S, Mauro L and Andò S: Interfering role of ERα on adiponectin action in breast cancer. Front Endocrinol (Lausanne). 11:662020. View Article : Google Scholar : PubMed/NCBI
15	Li J, Zhang T, Yang F, He Y, Dai F, Gao D, Chen Y, Liu M and Yi Z: Inhibition of breast cancer progression by a novel histone deacetylase inhibitor, LW479, by down-regulating EGFR expression. Br J Pharmacol. 172:3817–3830. 2015. View Article : Google Scholar : PubMed/NCBI
16	Newman DJ and Cragg GM: Natural products as sources of new drugs over the last 25 years. J Nat Prod. 70:461–477. 2007. View Article : Google Scholar : PubMed/NCBI
17	Connolly JD and Hill RA: Triterpenoids. Nat Prod Rep. 24:465–486. 2007. View Article : Google Scholar : PubMed/NCBI
18	Dzubak P, Hajduch M, Vydra D, Hustova A, Kvasnica M, Biedermann D, Markova L, Urban M and Sarek J: Pharmacological activities of natural triterpenoids and their therapeutic implications. Nat Prod Rep. 23:394–411. 2006. View Article : Google Scholar : PubMed/NCBI
19	Na M, Min BS, An RB, Jin W, Kim YH, Song KS, Seong YH and Bae K: Effect of the rhizomes of Astilbe chinensis on UVB-induced inflammatory response. Phytother Res. 18:1000–1004. 2004. View Article : Google Scholar : PubMed/NCBI
20	Sun HX, Ye YP and Pan YJ: Cytotoxic oleanane triterpenoids from the rhizomes of Astilbe chinensis (Maxim.) Franch. et Savat. J Ethnopharmacol. 90:261–265. 2004. View Article : Google Scholar : PubMed/NCBI
21	Hu JY, Yao Z, Xu YQ, Takaishi Y and Duan HQ: Triterpenes from Astilbe chinensis. J Asian Nat Prod Res. 11:236–242. 2009. View Article : Google Scholar : PubMed/NCBI
22	Tae IH, Son JY, Lee SH, Ahn MY, Yoon K, Yoon S, Moon HR and Kim HS: A new SIRT1 inhibitor, MHY2245, induces autophagy and inhibits energy metabolism via PKM2/mTOR pathway in human ovarian cancer cells. Int J Biol Sci. 16:1901–1916. 2020. View Article : Google Scholar : PubMed/NCBI
23	Ding J, Liu J, Zhang Z, Guo J, Cheng M, Wan Y, Wang R, Fang Y, Guan Z, Jin Y and Xie SS: Design, synthesis and biological evaluation of coumarin-based N-hydroxycinnamamide derivatives as novel histone deacetylase inhibitors with anticancer activities. Bioorg Chem. 101:1040232020. View Article : Google Scholar : PubMed/NCBI
24	Li Y and Seto E: HDACs and HDAC inhibitors in cancer development and therapy. Cold Spring Harb Perspect Med. 6:a0268312016. View Article : Google Scholar : PubMed/NCBI
25	Li Y, Yuan YY, Meeran SM and Tollefsbol TO: Synergistic epigenetic reactivation of estrogen receptor-α (ERα) by combined green tea polyphenol and histone deacetylase inhibitor in ERα-negative breast cancer cells. Mol Cancer. 9:2742010. View Article : Google Scholar : PubMed/NCBI
26	Millot C, Millot JM, Morjani H, Desplaces A and Manfait M: Characterization of acidic vesicles in multidrug-resistant and sensitive cancer cells by acridine orange staining and confocal microspectrofluorometry. J Histochem Cytochem. 45:1255–1264. 1997. View Article : Google Scholar : PubMed/NCBI
27	Dong C, Wu J, Chen Y, Nie J and Chen C: Activation of PI3K/AKT/mTOR pathway causes drug resistance in breast cancer. Front Pharmacol. 12:6286902021. View Article : Google Scholar : PubMed/NCBI
28	Cras A, Darsin-Bettinger D, Balitrand N, Cassinat B, Soulié A, Toubert ME, Delva L and Chomienne C: Epigenetic patterns of the retinoic acid receptor beta2 promoter in retinoic acid-resistant thyroid cancer cells. Oncogene. 26:4018–4024. 2007. View Article : Google Scholar : PubMed/NCBI
29	Godman CA, Joshi R, Tierney BR, Greenspan E, Rasmussen TP, Wang HW, Shin DG, Rosenberg DW and Giardina C: HDAC3 impacts multiple oncogenic pathways in colon cancer cells with effects on Wnt and vitamin D signaling. Cancer Biol Ther. 7:1570–1580. 2008. View Article : Google Scholar : PubMed/NCBI
30	Zhang XH, Wang Z, Kang BG, Hwang SH, Lee JY, Lim SS and Huang B: Antiobesity effect of Astilbe chinensis Franch. et Savet. Extract through regulation of adipogenesis and AMP-activated protein kinase pathways in 3T3-L1 adipocyte and high-fat diet-induced C57BL/6N obese mice. Evid Based Complement Alternat Med. 2018:13476122018. View Article : Google Scholar : PubMed/NCBI
31	Sancheti S, Sancheti S, Lee SH, Lee JE and Seo SY: Screening of Korean medicinal plant extracts for α-glucosidase inhibitory activities. Iran J Pharm Res. 10:261–264. 2011.PubMed/NCBI
32	Gil TY, Jin BR, Hong CH, Park JH and An HJ: Astilbe chinensis ethanol extract suppresses inflammation in macrophages via NF-κB pathway. BMC Complement Med Ther. 20:3022020. View Article : Google Scholar : PubMed/NCBI
33	Zhang YB, Ye YP, Wu XD and Sun HX: Astilbotriterpenic acid induces growth arrest and apoptosis in HeLa cells through mitochondria-related pathways and reactive oxygen species (ROS) production. Chem Biodivers. 6:218–230. 2009. View Article : Google Scholar : PubMed/NCBI
34	Häcker G: The morphology of apoptosis. Cell Tissue Res. 301:5–17. 2000. View Article : Google Scholar : PubMed/NCBI
35	Zeiss CJ: The apoptosis-necrosis continuum: Insights from genetically altered mice. Vet Pathol. 40:481–495. 2003. View Article : Google Scholar : PubMed/NCBI
36	Vermeulen K, Van Bockstaele DR and Berneman ZN: The cell cycle: A review of regulation, deregulation and therapeutic targets in cancer. Cell Prolif. 36:131–149. 2003. View Article : Google Scholar : PubMed/NCBI
37	Nigg EA: Cyclin-dependent protein kinases: Key regulators of the eukaryotic cell cycle. Bioessays. 17:471–480. 1995. View Article : Google Scholar : PubMed/NCBI
38	Malumbres M and Barbacid M: Cell cycle, CDKs and cancer: A changing paradigm. Nat Rev Cancer. 9:153–166. 2009. View Article : Google Scholar : PubMed/NCBI
39	Satyanarayana A and Kaldis P: Mammalian cell-cycle regulation: Several Cdks, numerous cyclins and diverse compensatory mechanisms. Oncogene. 28:2925–2939. 2009. View Article : Google Scholar : PubMed/NCBI
40	Sauer K and Lehner CF: The role of cyclin E in the regulation of entry into S phase. Prog Cell Cycle Res. 1:125–139. 1995. View Article : Google Scholar : PubMed/NCBI
41	Peter M: The regulation of cyclin-dependent kinase inhibitors (CKIs). Prog Cell Cycle Res. 3:99–108. 1997. View Article : Google Scholar : PubMed/NCBI
42	Elmore S: Apoptosis: A review of programmed cell death. Toxicol Pathol. 35:495–516. 2007. View Article : Google Scholar : PubMed/NCBI
43	Hengartner MO: The biochemistry of apoptosis. Nature. 407:770–776. 2000. View Article : Google Scholar : PubMed/NCBI
44	Miyashita T, Krajewski S, Krajewska M, Wang HG, Lin HK, Liebermann DA, Hoffman B and Reed JC: Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo. Oncogene. 9:1799–1805. 1994.PubMed/NCBI
45	Vaux DL, Cory S and Adams JM: Bcl-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells. Nature. 335:440–442. 1988. View Article : Google Scholar : PubMed/NCBI
46	Pietenpol JA and Stewart ZA: Cell cycle checkpoint signaling: Cell cycle arrest versus apoptosis. Toxicology. 181–182. 475–481. 2002.PubMed/NCBI
47	Beneke R, Geisen C, Zevnik B, Bauch T, Müller WU, Küpper JH and Möröy T: DNA excision repair and DNA damage-induced apoptosis are linked to Poly(ADP-ribosyl)ation but have different requirements for p53. Mol Cell Biol. 20:6695–6703. 2000. View Article : Google Scholar : PubMed/NCBI
48	Galluzzi L and Green DR: Autophagy-independent functions of the autophagy machinery. Cell. 177:1682–1699. 2019. View Article : Google Scholar : PubMed/NCBI
49	Apel A, Herr I, Schwarz H, Rodemann HP and Mayer A: Blocked autophagy sensitizes resistant carcinoma cells to radiation therapy. Cancer Res. 68:1485–1494. 2008. View Article : Google Scholar : PubMed/NCBI
50	Döring T, Zeyen L, Bartusch C and Prange R: Hepatitis B virus subverts the autophagy elongation complex Atg5-12/16L1 and does not require Atg8/LC3 lipidation for viral maturation. J Virol. 92:e01513–e01517. 2018. View Article : Google Scholar : PubMed/NCBI
51	Li F, Guo H, Yang Y, Feng M, Liu B, Ren X and Zhou H: Autophagy modulation in bladder cancer development and treatment (review). Oncol Rep. 42:1647–1655. 2019.PubMed/NCBI
52	Perez EA: Microtubule inhibitors: Differentiating tubulin-inhibiting agents based on mechanisms of action, clinical activity, and resistance. Mol Cancer Ther. 8:2086–2095. 2009. View Article : Google Scholar : PubMed/NCBI
53	Dumontet C and Jordan MA: Microtubule-binding agents: A dynamic field of cancer therapeutics. Nat Rev Drug Discov. 9:790–803. 2010. View Article : Google Scholar : PubMed/NCBI
54	Jordan VC: Chemoprevention of breast cancer with selective oestrogen-receptor modulators. Nat Rev Cancer. 7:46–53. 2007. View Article : Google Scholar : PubMed/NCBI
55	Younis AM, Wu FS and El Shikh HH: Antimicrobial activity of extracts of the oyster culinary medicinal mushroom Pleurotus ostreatus (higher basidiomycetes) and identification of a new antimicrobial compound. Int J Med Mushrooms. 17:579–590. 2015. View Article : Google Scholar : PubMed/NCBI